Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model

15 Mar 2021

Abstract excerpt

EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). It is highly active against all RSV-A and B laboratory strains and clinical isolates tested in vitro in various cell lines and assays, with half-maximal effective concentrations (EC50s) of 21, 23 and 64 nM against Long (A), M37 (A) and VR-955 (B) strains, respectively, in the primary human bronchial epithelial cells (HBECs)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parvovirus B19 Infection Studies
Share to Respiratory viral infections research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33720995
DOI: 10.1371/journal.ppat.1009428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate modelPMID 33720995Read ↗

Orally active fusion inhibitor of respiratory syncytial virus.Semantic proximity Read ↗

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.Semantic proximity Read ↗

Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeysSemantic proximity Read ↗

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604Semantic proximity Read ↗

Antiviral drug synergy and mutational signatures in different epithelial cell models of RSV and hPIV infectionSemantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

Discovery of a Novel Respiratory Syncytial Virus Replication InhibitorSemantic proximity Read ↗

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA VirusesSemantic proximity Read ↗

Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.Semantic proximity Read ↗

Structure-guided design of small-molecule therapeutics against RSV diseaseSemantic proximity Read ↗

Characterization of a Respiratory Syncytial Virus L Protein InhibitorSemantic proximity Read ↗

Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.